EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access

Impact assessment of [18F]FDG PET/CT in predicting EGFR gene mutation status in patients with lung adenocarcinoma using recovery coefficient-based correction of semi-quantitative and volume-based PET metrics

Aleksei Leontev, Angelina Lokhova, Aleksandr Khalimon, Malika Khodzhibekova, Tatyana Lazutina, Gulnara Khamadeeva, Daria Khodakova, Irina Pylova, Vitaly Bobrov, Leila Atakishieva, Natalia Kadymova, Anastasia Nikiforuk und 5 weitere

Nuklearmedizin - NuclearMedicine · 01.06.2026 · 65 (03) · 199-206

DOI: 10.1055/a-2777-2278 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Nuklearmedizin - NuclearMedicine, erschienen am 01.06.2026. Verfasst von Aleksei Leontev und 16 weiteren Autor:innen. Beteiligte Einrichtung: P. Hertsen Moscow Oncology Research Institute - the branch of the FSBI "National Medical Research Radiological Centre" of the Ministry of Health of t…. Hauptthemen laut MEDLINE: Adenocarcinoma of Lung, ErbB Receptors, Fluorodeoxyglucose F18, Lung Neoplasms. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aim

The aim of this study was to assess the impact of [18F]FDG PET/CT in predicting EGFR gene mutation status in patients with lung adenocarcinoma using recovery coefficient-based (RC-based) correction of semi-quantitative and volume-based PET metrics.

Methods

A retrospective multi-center study included 63 patients diagnosed with lung adenocarcinoma who underwent [18F]FDG PET/CT. Acquisition was performed according to the EANM guidelines using two EARL-accredited PET/CT-systems. All patients were divided into an EGFR-mutant (n=30) and a wild-type (n=33) groups based on the results of molecular testing. Maximal diameter and CT volume of each primary tumor lesion were measured. [18F]FDG uptake was evaluated by measurement of semi-quantitative and volume-based PET metrics such as SUVmax, SUVpeak, MTV, and TLG. TLG was measured using PET segmentation method by 3D-Isocontour tool with a 41% of SUVmax threshold (TLG41%) and a threshold adapted to the CT volume (TLGCT). Additionally, TLR was calculated as the ratio of tumor SUVpeak to liver SUVmean. Acquisition data of the NEMA IEC Body Phantom Set NU2–2018 were applied for plotting the RC curves which were used for following RC-based correction of PET metrics.

Results

No significant difference in tumor lesion maximal diameter, CT volume, evaluated values of PET metrics before and after RC-based correction was found between the EGFR-mutant and wild-type groups (p > 0.05).

Conclusion

Observed semi-quantitative and volume-based PET metrics obtained from [18F]FDG PET/CT have no significant value for predicting EGFR gene mutation status in patients with lung adenocarcinoma, regardless of whether RC-based correction is applied.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Adenocarcinoma of LungErbB ReceptorsFluorodeoxyglucose F18Lung NeoplasmsPositron Emission Tomography Computed TomographyAgedFemaleHumansMaleMiddle AgedAdenocarcinomaMutationRadiopharmaceuticalsRetrospective Studies

Substanzen

EGFR protein, humanErbB ReceptorsFluorodeoxyglucose F18Radiopharmaceuticals

Autor:innen und Institutionen

  • P. Hertsen Moscow Oncology Research Institute - the branch of the FSBI "National Medical Research Radiological Centre" of the Ministry of Health of the Russian Federation, Department of Nuclear Medicine, Russian Federat…
  • N. Lopatkin Scientific Research Institute of Urology and Interventional Radiology - the branch of the FSBI "National Medical Research Radiological Centre" of the Ministry of Health of the Russian Federation, Department…
  • National Medical Research Radiological Centre, Russian Federation, Obninsk.
  • Medical Institute of Peoples' Friendship University of Russia, Russian Federation, Moscow.

Zitieren

APA

Leontev, A., Lokhova, A., Khalimon, A., Khodzhibekova, M., Lazutina, T., Khamadeeva, G., Khodakova, D., Pylova, I., Bobrov, V., Atakishieva, L., Kadymova, N., Nikiforuk, A., Shvets, B., Volchenko, N., Surkova, V., Shatalov, P., & Kaprin, A. (2026). Impact assessment of [18F]FDG PET/CT in predicting EGFR gene mutation status in patients with lung adenocarcinoma using recovery coefficient-based correction of semi-quantitative and volume-based PET metrics. Nuklearmedizin - NuclearMedicine, 65(03), 199-206. https://doi.org/10.1055/a-2777-2278

Vancouver

Leontev A, Lokhova A, Khalimon A, Khodzhibekova M, Lazutina T, Khamadeeva G, et al. Impact assessment of [18F]FDG PET/CT in predicting EGFR gene mutation status in patients with lung adenocarcinoma using recovery coefficient-based correction of semi-quantitative and volume-based PET metrics. Nuklearmedizin - NuclearMedicine. 2026;65(03):199-206. doi:10.1055/a-2777-2278

BibTeX
@article{Leontev2026,
  author = {Leontev, Aleksei and Lokhova, Angelina and Khalimon, Aleksandr and Khodzhibekova, Malika and Lazutina, Tatyana and Khamadeeva, Gulnara and Khodakova, Daria and Pylova, Irina and Bobrov, Vitaly and Atakishieva, Leila and Kadymova, Natalia and Nikiforuk, Anastasia and Shvets, Bogdan and Volchenko, Nadezhda and Surkova, Viktoriya and Shatalov, Petr and Kaprin, Andrey},
  title = {Impact assessment of [18F]FDG PET/CT in predicting EGFR gene mutation status in patients with lung adenocarcinoma using recovery coefficient-based correction of semi-quantitative and volume-based PET metrics},
  journal = {Nuklearmedizin - NuclearMedicine},
  year = {2026},
  volume = {65},
  number = {03},
  pages = {199--206},
  doi = {10.1055/a-2777-2278}
}
Kostenlos starten →